Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Navigating the complexity of ulcerative colitis

Challenging case example

Mark Lees, Loren Regier and Brent Jensen
Canadian Family Physician May 2011, 57 (5) 568-572;
Mark Lees
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren Regier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: regierl@rxfiles.ca
Brent Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF
Loading

Diagnosis …

Mr E.K. is a 42-year-old construction worker who was diagnosed with ulcerative colitis (UC) 3 years ago after presenting to the emergency department with a 2-week history of bloody diarrhea, lower abdominal pain, and tenesmus. A gastroenterology consultation resulted in flexible sigmoidoscopy with findings supporting the diagnosis of colitis, including fibropurulent exudate found continuously from the rectum to 30 cm. No risk factors for infectious or Clostridium difficile–associated colitis were identified. Mr E.K. denied any extraintestinal features of inflammatory bowel disease (IBD). He was admitted to hospital for rehydration, symptom control, and medical management of presumed UC. Biopsies obtained during sigmoidoscopy were consistent with a diagnosis of IBD. Oral prednisone, 40 mg once daily, was initiated and he was discharged 1 week later with substantial improvement in his symptoms and a plan to taper the prednisone by 5 mg weekly.

First remission …

At a follow-up gastroenterology appointment 6 weeks later, Mr E.K. reported that although he was feeling much better, he continued to experience frequent, bloody bowel movements (up to 8 per day). His prednisone dose had been tapered to 10 mg once daily. Findings of physical examination were unremarkable. Oral 5-aminosalicylic acid (5-ASA), 1 g 3 times a day, was initiated, as was supplementation with the probiotic VSL#3. He continued tapering his prednisone by 2.5 mg weekly without a reoccurrence of symptoms. The 5-ASA dose was also eventually changed to a maintenance dose of 1.5 g twice daily.

Bringing evidence to practice

  • Table 11–7 provides an overview of common drugs used in the treatment of UC.* Oral corticosteroids are usually reserved for UC patients who do not respond to oral sulfasalazine or 5-ASA with or without topical 5-ASA, although they are also suitable for systemically ill patients. The time to effect is 7 to 14 days.2 Following this, a gradual tapering of the dose is important to reduce symptom relapse.

  • If 5-ASA is used for acute UC, the combination of both oral and topical rectal formulations is more effective than either alone.8,9 While oral 5-ASA is given daily, 5-ASA enemas might only be necessary twice weekly (for both acute and maintenance UC treatment). Combination oral and rectal therapy also allows for lower oral 5-ASA doses, which might reduce the risk of adverse events such as blood dyscrasias and hepatotoxicity.10 Both oral and rectal 5-ASA products vary in their formulations, affecting their activity in various areas of the lower bowel. Sulfasalazine and 5-ASA are similarly effective; sulfasalazine is less expensive but might be poorly tolerated.

  • The probiotic VSL#3 has limited evidence suggesting possible benefit in maintenance treatment of mild to moderate UC.6

View this table:
  • View inline
  • View popup
Table 1

Overview of common drugs for the treatment of UC

Difficult year …

Mr E.K. continued to be closely followed by his family physician and gastroenterologist. He experienced multiple exacerbations of his IBD symptoms, each managed with a tapering course of prednisone. During his fourth exacerbation, the decision was made to initiate azathioprine at a dose of 50 mg once daily, with plans to add 25 mg weekly to a target dose of 100 mg/d. He continued taking the 5-ASA. Prednisone was restarted at 30 mg once daily and successfully tapered by 5 mg every week without a reoccurrence of his symptoms. At a follow-up appointment with his gastroenterologist, his azathioprine dose was increased to 150 mg once daily. Mr E.K.’s dose of 5-ASA was increased to 1.5 g 3 times daily in hopes of maintaining remission.

Three months after starting the azathioprine, Mr E.K. developed diffuse myalgia and subjective muscle weakness of the upper and lower extremities. At work, he had difficulty with overhead lifting and climbing ladders. His serum creatine kinase level was elevated at 589 U/L. Complete blood count, creatinine, electrolyte, liver enzyme, and thyroid-stimulating hormone levels were within normal limits. Mr E.K.’s azathioprine was stopped, with resolution of his muscle symptoms during the next 4 weeks. His creatine kinase level decreased slightly to 524 U/L. Mr E.K.’s gastroenterologist considered initiating a biologic response modifier such as infliximab.

Bringing evidence to practice

  • Azathioprine (1.5 to 2.5 mg/kg daily) might be effective in addition to 5-ASA as maintenance therapy for UC patients who require ongoing or frequent steroid treatment (off-label use).11 As the onset of effect is slow, allow up to 6 months before reassessing therapy. In Mr E.K.’s case, was the dose too high too soon? It is possible that a longer trial at the 100-mg daily dose might have resulted in further benefit without the increased risk of adverse events associated with an increased dose.12

  • With the frequent use of prednisone, consideration should be given to the need for osteoporosis prevention measures such as lifestyle modifications (eg, smoking cessation, exercise) and supplementation with vitamin D (eg, 1000 IU daily) and calcium (to ensure 1200 mg total daily intake of elemental calcium). A thorough fracture risk assessment is important and would guide evaluation of the need for a bisphosphonate.13

  • Biologics such as infliximab suppress the immune system and increase infection risk. This risk is further increased if a patient is concomitantly taking other immune suppressants. When diagnosing UC, the eventual need for a biologic response modifier and the resulting immunosuppression should be considered. With this potential, consider the need for chest x-ray scan, tuberculosis and hepatitis screening, and administration of any necessary live vaccines. Standard vaccines should be administered when appropriate, including tetanus, diphtheria, poliomyelitis, human papillomavirus, varicella, herpes zoster, influenza, pneumococcal, hepatitis A and B, and measles-mumps-rubella. Thereafter, patients should receive annual inactivated influenza vaccines.14–16

Another admission and another medication …

Within weeks of discontinuing the azathioprine, Mr E.K. experienced a severe flare of IBD symptoms, with up to 16 bloody bowel motions per day, disabling fatigue, and left lower quadrant pain relieved with defecation. He was admitted to hospital for further investigation and treatment. He received 2 units of packed red blood cells for anemia (hemoglobin 85 g/L). A limited colonoscopy revealed severe colitis and numerous scattered pseudopolyps and surrounding ulcerations. Biopsy results demonstrated florid acute and chronic inflammation. The acute exacerbation was treated with intravenous (IV) corticosteroids, and infliximab induction began with the first of 3, 300-mg IV doses. After 1 week he was discharged taking prednisone, 20 mg twice daily, to be tapered slowly during the next 2 months. Arrangements were made for Mr E.K. to receive follow-up infliximab infusions at 2, 6, and 14 weeks after induction, then to continue receiving infusions every 8 weeks if the prednisone was successfully tapered. With his third and fourth infliximab infusions, Mr E.K. experienced acute transfusion reactions, with symptoms of fever, headache, flushing, and hypotension. This occurred despite pretreatment with 50 mg of oral diphenhydramine and 100 mg of IV hydrocortisone. He was reluctant to continue with the infliximab. As a result, therapy with adalimumab was initiated at 160 mg subcutaneously every other week for 2 doses, then 40 mg subcutaneously every 2 weeks. He continued to take 1.5 g of oral 5-ASA 3 times daily.

Bringing evidence to practice

  • Fulminant, severe UC exacerbations can be managed by IV corticosteroids.17 A significant clinical effect would be expected within 7 to 10 days. In patients who do not improve with this treatment, there is evidence that infliximab might be effective in inducing remission (number needed to treat is 5 at 8 weeks).18–20 Biologic therapies usually take effect within 2 weeks.

  • Infusion reactions and delayed hypersensitivity-like reactions (after 3 to 14 days) are common (approximately 10% of patients) with IV infliximab. Slowing the rate of infusion (over 2 to 4 hours) as well as pretreatment with acetaminophen, diphenhydramine, and IV hydrocortisone can reduce the incidence of reactions. Such reactions are uncommon with adalimumab, which is administered subcutaneously.

  • Monitoring of patients using biologic therapies should include careful surveillance for infection.21 Early detection, routine history and physician examination, and immediate initiation of supportive care are critical, as signs and symptoms might be blunted as a result of the anti-inflammatory effects of the biologic therapies. Tumour necrosis factor–α antagonists should be discontinued when there is clinical suspicion of infection and should not be restarted until the patient has stabilized. It is essential that the patient be educated about the early signs and symptoms of infection.

  • Probiotics should likely be stopped once a biologic agent is started, as continuation could theoretically increase the risk of infection.

  • With poor response to drug treatment or emergence of adverse events, the option of total colectomy as “curative” in UC should be entertained.

Serious complication …

One month after beginning adalimumab therapy, the patient once again reported a near complete resolution of his symptoms and a successful taper off of his prednisone. This remission lasted only 3 months, and Mr E.K. was restarted on 60 mg of prednisone for a severe flare of his symptoms. One week later, he began to complain of malaise, fever, and difficulty with balance. Over the following day, the fever worsened and he developed uncontrollable shaking of his upper limbs. That evening he slept on a reclining chair; the following morning he was found unresponsive by his wife and was transferred to hospital by ambulance with possible seizure activity en route. He was admitted to the intensive care unit and was eventually diagnosed with a limbic viral encephalitis. He remained in hospital for many months, experiencing numerous sequelae and complications, including ongoing gastrointestinal bleeding, recurrent sepsis, acute renal failure secondary to acute tubular necrosis, multiple deep vein thromboses, dysphonia, urinary incontinence, disequilibrium, and lower extremity weakness.

Three years after diagnosis, after several hospital admissions and numerous exacerbations, Mr E.K. underwent a total colectomy for definitive treatment of his UC.

Footnotes

  • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • ↵* The full version of the RxFiles Inflammatory Bowel Disease chart is available at www.cfp.ca. Go to the full text of the article online, then click on CFPlus in the menu at the top right-hand side of the page.

  • Competing interests

    RxFiles and contributing authors do not have any commercial competing interests. RxFiles Academic Detailing Program is funded through a grant from Saskatchewan Health to Saskatoon Health Region; additional “not for profit; not for loss” revenue is obtained from sales of books and online subscriptions.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Linblad A,
    2. Regier L,
    3. Jensen B
    . Inflammatory bowel disease agents. RxFiles Drug Comparison Charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010. Available from: www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-IBD-UCCrohns.pdf. Accessed 2011 Feb 10.
  2. ↵
    1. Kornbluth A,
    2. Sachar DB,
    3. Practice Parameters Committee of the American College of Gastroenterology
    . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105(3):501-23.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bernstein CN,
    2. Fried M,
    3. Krabshuis JH,
    4. Cohen H,
    5. Eliakim R,
    6. Fedail S,
    7. et al
    . World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16(1):112-24.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sadowski DC,
    2. Bernstein CN,
    3. Bitton A,
    4. Croitoru K,
    5. Fedorak RN,
    6. Griffiths A,
    7. et al
    . Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn’s disease. Can J Gastroenterol 2009;23(3):185-202.
    OpenUrlPubMed
  5. ↵
    1. Singh JA,
    2. Wells GA,
    3. Christensen R,
    4. Tanjong Ghogomu E,
    5. Maxwell L,
    6. MacDonald JK,
    7. et al
    . Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794.
  6. ↵
    1. Tursi A,
    2. Brandimarte G,
    3. Papa A,
    4. Giglio A,
    5. Elisei W,
    6. Giorgetti GM,
    7. et al
    . Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105(10):2218-27.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sutherland L,
    2. MacDonald JK
    . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544.
  8. ↵
    1. Marteau P,
    2. Probert CS,
    3. Lindgren S,
    4. Gassul M,
    5. Tan TG,
    6. Dignass A,
    7. et al
    . Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54(7):960-5.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Safdi M,
    2. DeMicco M,
    3. Sninsky C,
    4. Banks P,
    5. Wruble L,
    6. Deren J,
    7. et al
    . A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92(10):1867-71.
    OpenUrlPubMed
  10. ↵
    1. Marshall JK,
    2. Thabane M,
    3. Steinhart AH,
    4. Newman JR,
    5. Anand A,
    6. Irvine EJ
    . Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;(1):CD004115.
  11. ↵
    1. Timmer A,
    2. McDonald JW,
    3. MacDonald JK
    . Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478.
  12. ↵
    1. Gisbert JP,
    2. Linares PM,
    3. McNicholl AG,
    4. Maté J,
    5. Gomollón F
    . Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30(2):126-37.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Goodhand JR,
    2. Kamperidis N,
    3. Nguyen H,
    4. Wahed M,
    5. Rampton DS
    . Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011;33(5):551-8.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Rahier F,
    2. Ben-Horin S,
    3. Chowers Y,
    4. Conlon C,
    5. De Munter P,
    6. D’Haens G,
    7. et al
    . European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
    OpenUrlFREE Full Text
    1. Wasan SK,
    2. Baker SE,
    3. Skolnik PR,
    4. Farraye FA
    . A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010;105(6):1231-8.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Parihar K,
    2. Jensen B,
    3. Regier L
    . Vaccines, adult. RxFiles Drug Comparison Charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010. Available from: www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-Vaccine-Adult-andSK-Funded.pdf. Accessed 2011 Feb 15.
  16. ↵
    1. Lichtenstein GR,
    2. Abreu MT,
    3. Cohen R,
    4. Tremaine W,
    5. American Gastroenterological Association
    . American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):935-9.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rutgeerts P,
    2. Sandborn WJ,
    3. Feagan BG,
    4. Reinisch W,
    5. Olson A,
    6. Johanns J,
    7. et al
    . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76.
    OpenUrlCrossRefPubMed
    1. Gisbert JP,
    2. Gonzalez-Lama Y,
    3. Mate J
    . Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25(1):19-37.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lawson MM,
    2. Thomas AG,
    3. Akobeng AK
    . Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(3):CD005112.
  19. ↵
    1. Rahier JF,
    2. Ben-Horin S,
    3. Chowers Y,
    4. Conlon C,
    5. De Munter P,
    6. D’Haens G,
    7. et al
    . European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47-91.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 57 (5)
Canadian Family Physician
Vol. 57, Issue 5
1 May 2011
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Navigating the complexity of ulcerative colitis
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Navigating the complexity of ulcerative colitis
Mark Lees, Loren Regier, Brent Jensen
Canadian Family Physician May 2011, 57 (5) 568-572;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Navigating the complexity of ulcerative colitis
Mark Lees, Loren Regier, Brent Jensen
Canadian Family Physician May 2011, 57 (5) 568-572;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Diagnosis …
    • First remission …
    • Bringing evidence to practice
    • Difficult year …
    • Bringing evidence to practice
    • Another admission and another medication …
    • Bringing evidence to practice
    • Serious complication …
    • Footnotes
    • References
  • Figures & Data
  • CFPlus
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Spontaneous pneumothorax in children
  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
Show more Practice

RxFiles

  • Providing HIV preexposure prophylaxis
  • Offrir une prophylaxie préexposition contre le VIH
  • Medication management for heart failure with reduced ejection fraction
Show more RxFiles

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire